pharma m&a BioPharma M&A Drives More Efficient Resource Allocation By feedproxy.google.com Published On :: Mon, 02 Mar 2020 13:01:16 +0000 M&A is an omnipresent reality in the biopharma industry, from Big Pharma mega-mergers to smaller acquisitions of emerging startups. We’ve recently witnessed several large M&A transactions get closed or announced, including BMS-Celgene, Takeda-Shire, and AbbVie-Allergan; according to BMO Capital Markets The post BioPharma M&A Drives More Efficient Resource Allocation appeared first on LifeSciVC. Full Article Biotech financing Capital efficiency Capital markets Exits IPOs M&As External R&D Pharma industry R&D Productivity Biotech M&A M&A Pharma M&A Pharma mega-merger
